bioRxivBiochemistry
A simple assay for inhibitors of mycobacterial oxidative phosphorylation
Abstract
Oxidative phosphorylation, the combined activities of the electron transport chain (ETC) and adenosine triphosphate (ATP) synthase, has emerged as a valuable target for antibiotics to treat infection with Mycobacterium tuberculosis and related pathogens. In oxidative phosphorylation, the ETC establishes a transmembrane electrochemical proton gradient that powers ATP synthesis. Monitoring oxidative phosphorylation with luciferase-based detection of ATP synthesis or measurement of oxygen consumption can be technically challenging and expensive. These limitations reduce the utility of these methods for characterization of mycobacterial oxidative phosphorylation inhibitors. Here we show that fluorescence-based measurement of acidification of inverted membrane vesicles (IMVs) can detect and distinguish between inhibition of the ETC, inhibition of ATP synthase, and non-specific membrane uncoupling. In this assay, IMVs from M. smegmatis are acidified either through the activity of the ETC or ATP synthase, the latter modified genetically to allow it to serve as an ATP-driven proton pump. Acidification is monitored by fluorescence from 9-amino-6-chloro-2-methoxyacridine, which accumulates and quenches in acidified IMVs. Non-specific membrane uncouplers prevent both succinate- and ATP-driven IMV acidification. In contrast, the ETC Complex III2IV2 inhibitor telacebec (Q203) prevents succinate-driven acidification but not ATP-driven acidification and the ATP synthase inhibitor bedaquiline prevents ATP-driven acidification but not succinate-driven acidification. We use the assay to show that, as proposed previously, lansoprazole sulfide is an inhibitor of Complex III2IV2 while thioridazine uncouples the mycobacterial membrane non-specifically. Overall, the assay is simple, low cost, and scalable, which will make it useful for identifying and characterizing new mycobacterial oxidative phosphorylation inhibitors.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure of mycobacterial CIII2CIV2 respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203)
D. J. Yanofsky, J. M. Di Trani, … J. L. Rubinstein·bioRxiv·Jul 6, 2021
- Structural basis for inhibition of mycobacterial ATP synthase by squaramides and second generation diarylquinolines
G. M. Courbon, P. R. Palme, … J. L. Rubinstein·bioRxiv·Feb 3, 2023
- Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis
Arnab Roy, Satish Kushwah, … Nitin Pal Kalia·bioRxiv·Nov 23, 2025
- MmpL3 is the flippase for mycolic acids in mycobacteria
Z. Xu, V. A. Meshcheryakov, … S. S. Chng·bioRxiv·May 3, 2017
- Structure of mycobacterial respiratory Complex I
Y. Liang, A. Plourde, … J. L. Rubinstein·bioRxiv·Oct 4, 2022
- Impaired succinate oxidation prevents growth and influences drug susceptibility in Mycobacterium tuberculosis
C. R. Adolph, M. B. McNeil, G. M. Cook·bioRxiv·Jun 21, 2021